Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
WTWalter TaalHMHendrika M. OosterkampAWAnnemiek WalenkampHJHendrikus J. DubbinkLVLaurens V. Beerepoot
Erasmus MC Cancer Institute · Medisch Centrum Haaglanden · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
751
total citations
- FWCI
- 43.71
- Percentile
- 100%
- References
- 38
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Lomustine
- Bevacizumab
- Medicine
- Temozolomide
- Internal medicine
- Progression-free survival
- Clinical endpoint
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.